Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.03 EUR
Change Today -0.173 / -7.84%
Volume 33.1K
VPA On Other Exchanges
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (VPA) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - €3.02
52 Week Low
12/11/14 - €0.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

aveo pharmaceuticals inc (VPA) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (VPA) Details

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. The company’s development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

57 Employees
Last Reported Date: 03/6/15
Founded in 2001

aveo pharmaceuticals inc (VPA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $504.1K
Executive Officer
Total Annual Compensation: $480.3K
Chief Financial Officer
Total Annual Compensation: $350.9K
Compensation as of Fiscal Year 2014.

aveo pharmaceuticals inc (VPA) Key Developments

AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma

AVEO Oncology announced that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The Company previously reported interim median progression free survival (PFS) results of 8.4 months among the 163 patients enrolled in Study 902. Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population. AVEO also announced that it has received a written response from the U.S. Food and Drug Administration (FDA) stating that a phase 3 study outlined by the Company, in patients with RCC who have failed at least two prior regimens, including VEGF therapy, “may support AVEO’s proposed indication for tivozanib in the 3rd line setting.” In response to whether the study, together with the TIVO-1 study, would be sufficient to support licensure of tivozanib as a treatment for advanced RCC, the FDA indicated: “whether the results from this study can support AVEO’s proposal for tivozanib in the first line setting is a review issue. The study design shared with the FDA is a randomized, controlled, multi-center, open-label Phase 3 study of approximately 314 subjects randomized 1:1 to receive either tivozanib or sorafenib. Subjects enrolled in the study may include those who have received prior immunotherapy, including immune checkpoint (PD-1) inhibitors, reflecting a potentially evolving treatment landscape. The primary objective of the study would be PFS. Secondary objectives would include OS and objective response rate (ORR) as well as safety and pharmacokinetic endpoints.

AVEO Oncology Announces Unaudited Consolidated Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Third Quarter of 2016

AVEO Oncology announced unaudited consolidated earnings results for the first quarter of 2015. The company reported a wider-than-expected loss for the first quarter of 2015, but beat the analyst estimate by $0.04 per share. The company reported a net loss of $10.9 million, or $0.21 per share compared to for the same quarter last year, reported a loss of $6.4 million, or $0.12 per share. As a result of an additional one-time recognition of $14.1 million of previously deferred revenue as a result of the modification of Aveo's arrangement with Biogen Idec (BIIB), revenue was only $134,000 versus $15.3 million for first quarter of 2014. Total revenue was $10.283 million against $21.181 million a year ago. Loss from operations was $10.149 million against $5.892 million a year ago. The increase in the net loss is primarily driven by the additional one-time recognition of previously deferred revenue during first quarter of 2014, partially offset by the decrease in R&D and G&A expense. Based on its current operating plan, the company expects its $39.1 million in cash resources as of March 31, 2015 will be sufficient to fund operations into the third quarter of 2016.

AVEO Pharmaceuticals Seeks Acquisitions

AVEO Pharmaceuticals, Inc. (NasdaqGS:AVEO) is looking for acquisition opportunities. AVEO Pharmaceuticals, Inc. has filed a shelf registration in the amount of $100 million and intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include repayment and refinancing of debt, working capital and capital expenditures, research and development expenses, including clinical trial costs, general and administrative expenses, and potential acquisition of, or investment in, companies, technologies, products or assets that complement our business.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPA:GR €2.03 EUR -0.173

VPA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.81 USD -0.065
Bristol-Myers Squibb Co $68.30 USD -0.59
Exelixis Inc $3.15 USD +0.01
GlaxoSmithKline SAE £11.50 EGP -0.02
Takeda Pharmaceutical Co Ltd ¥6,004 JPY +29.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VPA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.0x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at